Inhibitory receptors including the killer cell immunoglobulin (Ig)‐like receptors (KIRs) bind MHC-I molecules to protect healthy cells from NK cell attack, while tumor cells downregulate MHC-I expression in an attempt to evade CD8+ T cell response and activate NK cell response. Here, CD8A is linked to neoplasm.